| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
2-Iodoadenosine targets adenosine receptors and adenosine-related pathways. As an adenosine analog, the compound may interact with adenosine receptors (A1, A2A, A2B, and A3) or affect adenosine metabolism. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, 2-Iodoadenosine can be used to study adenosine receptor binding and adenosine-related enzymatic activities. The compound's iodine substituent at the C2 position may affect its binding affinity and selectivity for different adenosine receptors. The compound is also used as an intermediate in the synthesis of isoguanosine.
|
| ln Vivo |
In cell-based assays, 2-Iodoadenosine may exhibit effects typical of adenosine analogs, including vasodilation and inhibition of cancer cell proliferation. The compound's effects on cell function are mediated through adenosine receptor signaling pathways. Further studies would be required to characterize the specific cellular activities of this compound.
|
| Enzyme Assay |
The cell-free assay for adenosine receptor binding typically involves competition binding experiments using radiolabeled adenosine analogs and membrane preparations from cells expressing specific adenosine receptors. The compound is incubated with membrane preparations and radiolabeled ligand, and bound radioactivity is measured after filtration. The IC50 or Ki for receptor binding is determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for adenosine analogs involve culturing mammalian cells and treating them with 2-Iodoadenosine at concentrations ranging from 0.1 to 100 μM. The effect on cell proliferation is assessed using MTT or CCK-8 assays. The effect on smooth muscle vasodilation can be assessed in isolated tissue preparations. The compound's effects on cancer progression are evaluated in cancer cell lines.
|
| Animal Protocol |
There is no established animal experimental protocol for 2-Iodoadenosine specifically. As an adenosine analog, the compound could potentially be evaluated in animal models for its vasodilatory or anti-cancer effects. Typical protocols for adenosine analogs involve administration to animals via intravenous or intraperitoneal routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Iodoadenosine have not been extensively reported. As a small molecule with molecular weight of 393.14 g/mol, the compound would be expected to have reasonable bioavailability and tissue penetration. The presence of the iodine atom may affect the compound's metabolic stability and distribution. Further pharmacokinetic studies would be required.
|
| Toxicity/Toxicokinetics |
Toxicity data for 2-Iodoadenosine are not well documented. As an adenosine analog, the compound may have effects on cardiovascular function due to its vasodilatory activity. Standard toxicity studies would be required to determine the safety profile.
|
| References | |
| Additional Infomation |
2-Iodoadenosine is a research compound used as an intermediate in nucleoside synthesis and to study adenosine analog biology. The compound is a halogenated adenosine analog with an iodine atom at the C2 position. It is used as an intermediate in the synthesis of isoguanosine. It is not an approved pharmaceutical and has no clinical trial history. This product is intended for research use only.
|
| Molecular Formula |
C10H12IN5O4
|
|---|---|
| Molecular Weight |
393.14
|
| Exact Mass |
392.993
|
| CAS # |
35109-88-7
|
| PubChem CID |
169662
|
| Appearance |
White to yellow solid powder
|
| Density |
2.7±0.1 g/cm3
|
| Boiling Point |
776.3±70.0 °C at 760 mmHg
|
| Melting Point |
200ºC (dec.)
|
| Flash Point |
423.3±35.7 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.994
|
| LogP |
-1.04
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)I)N
|
| InChi Key |
MGEBVSZZNFOIRB-UUOKFMHZSA-N
|
| InChi Code |
InChI=1S/C10H12IN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6-,9-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(6-amino-2-iodopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~254.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (12.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (12.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (12.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5436 mL | 12.7181 mL | 25.4362 mL | |
| 5 mM | 0.5087 mL | 2.5436 mL | 5.0872 mL | |
| 10 mM | 0.2544 mL | 1.2718 mL | 2.5436 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
